News that catches your eye Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : News that catches your eye

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zebity who wrote (109)	12/21/1998 3:43:00 PM
From: John Fairchild	Read Replies (1) of 148

This one is usually good for a runup on news - IMM-V Immune Network Research Ltd - Antibody patent issued Immune Network Research Ltd IMMShares issued 20,370,4521998-12-18 close $0.13Monday Dec 21 1998Mr. Victor Jones The United States Patent Office has issued a patent covering monoclonal antibody 1F7 (mAb 1F7) as United States Patent No. 5,849,583 titled Anti-idiotypic Antibody and its Use in Diagnosis and Therapy in HIV-Related Disease. The patent office abstract states, "The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds". The company has licenced mAb 1F7 from the Sydney Kimmel Cancer Centre and is conducting preclinical studies on macaques, which are a biological model for HIV disease in humans. The company may file divisional applications in respect of certain additional claims not allowed under the patent just issued. The company is waiting on responses from two laboratories in respect of bioassays on blood plasma prior to selection of the laboratory to analyze all of the plasma samples taken during its six month phase II preclinical trial of mAb 1F7. This study was designed to evaluate the beneficial effects of mAb 1F7 on levels of SHIV virus in the macaques and to test different SHIV clones. In an earlier study, mAb 1F7 was shown to both strengthen and broaden the immune response against the viral infection in the monkeys. Data from this study will be integral to the application to the FDA for approval of a human trial of mAb 1F7 under an Investigational New Drug protocol, which is the next milestone. The company has closed a previously announced private placement at $45,000 and will prepare for further financing in 1999 giving consideration to the patent just issued for mAb 1F7 and anticipated results from the phase II preclinical study. (c) Copyright 1998 Canjex Publishing Ltd. canada-stockwatch.com old url (better for printing)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next